Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications

Clearmind Medicine (Nasdaq: CMND) signed a new research agreement with Yissum to fund a 12‑month preclinical study of MEAI (CMND‑100) with tirzepatide in diet‑induced obese mice.

Rhea-AI Summary

Clearmind Medicine (Nasdaq: CMND) signed a new research agreement with Yissum to fund a 12‑month preclinical study of MEAI (CMND‑100) with tirzepatide in diet‑induced obese mice.

The study will assess combination and maintenance use in the fast‑growing $50–66B incretin therapeutics market.

Positive

• New 12‑month preclinical study of MEAI with tirzepatide in obese mice
• Prior MEAI data: approximately 15–20% body weight reduction in DIO mice
• MEAI effects included increased energy expenditure and fat utilization
• MEAI preserved lean mass and improved glucose homeostasis and hepatic steatosis in mice
• Targeting incretin market projected to reach $170–185B by 2033

Negative

• Current work is preclinical and limited to diet‑induced obese mouse models

Argus May 18 session

-26.90% close to close Open Argus

Details

News Market Reaction – CMND

On May 18, the day this news came out, CMND closed 26.90% below the previous close.

Data tracked by StockTitan Argus for the May 18 session.

Market Context

On May 18, the day this news came out, the stock closed 26.9% below the previous close. A negative r...

Analysis

On May 18, the day this news came out, the stock closed 26.9% below the previous close. A negative reaction despite today’s obesity-focused collaboration would fit a recent pattern where four of the last five updates, including clinical and IP milestones, saw next-day declines. Investors may be weighing the preclinical nature of this 12‑month DIO mouse study against existing financing structures, such as the Form F-3 covering up to 22,626,988 resale shares and remaining $10,000,000 convertible capacity. The large incretin market opportunity of $170–185 billion by 2033 contrasts with concerns over dilution and timelines.

Key Figures

Prior MEAI weight loss: 15–20% body weight reduction New study duration: 12 months Incretin market size 2025: $50–66 billion +5 more

Prior MEAI weight loss

15–20% body weight reduction

Diet-induced obese mice in prior Hebrew University study

New study duration

12 months

Preclinical MEAI–tirzepatide DIO mouse study

Incretin market size 2025

$50–66 billion

Global market for incretin-based therapies and tirzepatide in 2025

Incretin market 2033

$170–185 billion

Projected global incretin and tirzepatide market by 2033

Post-therapy weight regain

25% or more

Typical regain of lost weight within one year after GLP-1 discontinuation

MEAI indication

Alcohol Use Disorder

Ongoing FDA-approved Phase I/IIa trial of CMND-100 (MEAI)

Registered resale shares

22,626,988 common shares

Form F-3 for resale of note-conversion shares

Convertible facility capacity

$10,000,000

Remaining capacity for future convertible promissory note issuances as of 2026-04-30

Historical Context

5 past events · Latest: May 12

5 events

1. May 12

   Clinical milestone update

   24h Move

   +3.8%

   Phase I/IIa MEAI trial reaches 20 treated participants with no serious AEs.

2. May 11

   Investor webinar notice

   24h Move

   -5.6%

   Announcement of “Inside MEAI” webinar to review clinical data and updates.

3. May 05

   European patent filing

   24h Move

   -9.6%

   European patent filing for non-hallucinogenic compounds targeting PTSD and others.

4. Apr 27

   BTD evaluation news

   24h Move

   -10.1%

   Company evaluates MEAI for potential FDA Breakthrough Therapy Designation in AUD.

5. Apr 20

   Policy support highlight

   24h Move

   -28.1%

   Company highlights U.S. policy support for psychedelic therapies and its MEAI program.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

glp-1, gip, receptor agonists, incretin-based therapies, +4 more

8 terms

glp-1 medical

"GLP-1 and dual GLP-1/GIP receptor agonists primarily work by suppressing appetite"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

gip medical

"GLP-1 and dual GLP-1/GIP receptor agonists primarily work by suppressing appetite"

GIP commonly stands for Global Infrastructure Partners, a private investment firm that buys and manages large physical assets such as airports, power plants, toll roads and pipelines. Investors pay attention because when GIP acquires, invests in, or sells such assets it can alter cash flow, debt levels and long-term plans for those businesses—like a new landlord changing rents or making upgrades—affecting revenue, dividends and risk for shareholders and creditors.

receptor agonists medical

"GLP-1 and dual GLP-1/GIP receptor agonists primarily work by suppressing appetite"

Receptor agonists are drugs or molecules that bind to a cell’s receptor and activate it, triggering the cell to respond much like a key turning a lock to switch something on. For investors, agonists matter because their ability to safely and effectively activate biological targets drives a drug’s therapeutic value, clinical trial outcomes, regulatory approval prospects, and commercial potential, all of which influence a company’s future revenue and risk profile.

incretin-based therapies medical

"The global market for incretin-based therapies and tirzepatide has grown into a massive industry"

Drugs that mimic or enhance natural gut hormones called incretins, which help the body release insulin and lower blood sugar after meals. Think of them as a thermostat boost that helps the body respond better to rising glucose; some also reduce appetite and weight. Investors watch these therapies because they address large, growing markets for diabetes and obesity, can drive sizable drug sales, and often shape regulatory and competitive landscapes.

diet-induced obese ("dio") mice medical

"tirzepatide treatment in diet-induced obese ("DIO") mice"

Diet-induced obese (DIO) mice are laboratory animals fed a high-calorie diet to develop obesity and related metabolic conditions, used as a stand-in for human obesity in early-stage medical research. Investors care because results from DIO mouse studies act like crash-test dummies for potential drugs or devices—positive effects can de-risk a program and boost development value, while negative or non-translatable results can signal higher clinical and commercial risk.

hepatic steatosis medical

"improving glucose homeostasis and hepatic steatosis, Clearmind is now advancing MEAI"

Hepatic steatosis, often called fatty liver, is a condition where excess fat builds up in liver cells. For investors it matters because the condition drives demand for diagnostics, treatments and monitoring, can influence clinical trial outcomes and regulatory decisions, and affects healthcare costs—think of it like grease building up in an engine: it can slow performance, require repairs, and create market opportunities for companies offering solutions.

cardiometabolic medical

"delivering substantial weight loss and cardiometabolic improvements"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

maintenance therapy medical

"as a maintenance therapy following tirzepatide treatment in diet-induced obese ("DIO") mice"

Treatment given after an initial successful response to control a chronic or recurring disease and prevent it from returning or worsening; it often involves lower-intensity, ongoing medication or interventions rather than aggressive cures. For investors, maintenance therapy matters because it can create steady, long-term demand for drugs or services, similar to a subscription that generates predictable revenue and extends a product’s commercial life beyond the initial treatment period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the signing of a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. The agreement will fund a comprehensive preclinical study evaluating the metabolic efficacy of MEAI (CMND-100), both in combination with and as a maintenance therapy following tirzepatide treatment in diet-induced obese ("DIO") mice. The research will be conducted by Professor Joseph (Yossi) Tam and his team at the Obesity and Metabolism Laboratory at the Institute for Drug Research, School of Pharmacy, Hebrew University of Jerusalem.

The global market for incretin-based therapies and tirzepatide has grown into a massive industry valued at approximately $50–66 billion in 2025, and is projected to reach $170–185 billion by 2033. These therapies have significantly advanced the treatment of obesity and type 2 diabetes, delivering substantial weight loss and cardiometabolic improvements. Despite their remarkable success, GLP-1 and dual GLP-1/GIP receptor agonists primarily work by suppressing appetite and reducing energy intake. A major clinical challenge remains: substantial weight regain- often 25% or more of the lost weight within one year, along with partial reversal of metabolic benefits, frequently occurs upon discontinuation. This underscores the urgent need for complementary or maintenance strategies that can enhance treatment durability, help preserve lean muscle mass, and actively boost energy expenditure.

Building on positive results from its prior collaboration with Professor Yossi Tam’s laboratory at the Hebrew University, where MEAI demonstrated approximately 15–20% body weight reduction in DIO mice, primarily through increased energy expenditure and fat utilization while preserving lean mass and improving glucose homeostasis and hepatic steatosis, Clearmind is now advancing MEAI into combination and sequencing strategies with today’s leading incretin therapy.

The new 12-month study, titled “Assessing the Metabolic Efficacy of MEAI in Combination and Sequencing with Tirzepatide in Diet-Induced Obese Mice,” will examine: Additive or synergistic effects when MEAI is administered concomitantly with tirzepatide and the potential of MEAI as a maintenance therapy to attenuate post-tirzepatide weight regain and preserve metabolic benefits across multiple doses.

“MEAI is designed to offer a differentiated mechanism that potentially complements incretin therapies,” said Dr. Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind Medicine. “While those drugs excel at reducing food intake, our previous preclinical data show MEAI significantly enhances energy expenditure. We believe that this combination and maintenance approach has potential to deliver more robust, durable, and clinically meaningful outcomes for patients.”

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected growth of the global market for incretin-based therapies, how Clearmind is advancing MEAI into combination and sequencing strategies with today’s leading incretin therapy, how MEAI is designed to offer a differentiated mechanism that potentially complements incretin therapies and its belief that the combination and maintenance approach of MEAI and incretin therapies has potential to deliver more robust, durable, and clinically meaningful outcomes for patients. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Clearmind Medicine (CMND) announce on May 18, 2026 about MEAI and tirzepatide?

Clearmind Medicine announced a new research agreement to study MEAI (CMND‑100) with tirzepatide in obese mice. According to Clearmind, the 12‑month preclinical study will evaluate metabolic efficacy in combination and as maintenance therapy after tirzepatide treatment.

What is the goal of Clearmind Medicine’s new MEAI and tirzepatide preclinical study for CMND shareholders?

The study aims to assess whether MEAI can complement tirzepatide by enhancing and sustaining metabolic benefits. According to Clearmind, endpoints include potential additive or synergistic effects and attenuation of post‑tirzepatide weight regain in diet‑induced obese mice across multiple dosing regimens.

How effective was MEAI (CMND‑100) in previous Clearmind Medicine preclinical obesity studies?

Earlier preclinical work showed MEAI produced about 15–20% body weight reduction in diet‑induced obese mice. According to Clearmind, MEAI mainly increased energy expenditure and fat utilization while preserving lean mass and improving glucose homeostasis and hepatic steatosis metrics in these models.

Why is Clearmind Medicine exploring MEAI as maintenance therapy after tirzepatide for obesity?

Clearmind is targeting weight regain that often occurs after stopping GLP‑1 and dual GLP‑1/GIP agonists. According to Clearmind, MEAI will be tested as maintenance therapy to attenuate post‑tirzepatide weight regain and help preserve cardiometabolic improvements in preclinical mouse models.

What market opportunity does Clearmind Medicine see for MEAI in combination with tirzepatide (CMND)?

Clearmind is positioning MEAI within the rapidly expanding incretin‑based obesity and diabetes treatment market. According to Clearmind, this market was valued at roughly $50–66 billion in 2025 and is projected to grow to about $170–185 billion by 2033.

Who is conducting Clearmind Medicine’s MEAI and tirzepatide study and what will they examine?

The research will be led by Professor Joseph Tam’s team at Hebrew University’s Obesity and Metabolism Laboratory. According to Clearmind, investigators will examine concomitant MEAI and tirzepatide dosing and sequencing approaches to evaluate metabolic efficacy and durability of treatment effects in obese mouse models.